April.2015-March.2016

The Phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma

The completion of the cancer peptide vaccine ‘OTSGC-A24’ phase I/II clinical study for gastric cancer

The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia

Publication of a paper describing the possible effect of a TOPK inhibitor OTS514 and a MELK inhibitor OTS167 on kidney cancer

Publication for possible biomarkers of OTS167, MELK inhibitor

The completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma

Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer

The commencement of Phase Ib clinical study of the peptide vaccine for patients with malignant mesothelioma

The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA

MELK inhibitor, OTS167, Phase I clinical study commencement in Australia

Patent Registration for TOPK-specific inhibitors in Japan

Acceptance of a proposal on our compound for NCL characterization program

Publication from our collaborator in The University of Chicago

Publication from The University of Chicago and OncoTherapy Science

Commencement of T cell receptor (TCR) and B cell receptor (BCR) analysis business (follow-up report)

The completion of patient enrollment in Phase II clinical study of the cancer-specific peptide vaccine S-588410 in bladder cancer conducted by Shionogi & Co., Ltd

The termination of the agreement with Shionogi & Co., Ltd. on the peptide vaccine for disease in ophthalmic field

The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells

Publication from our collaborator in The University of Chicago

Announcement of the receipt of a notification of the achievement of a milestone associated with the progress of a Phase III clinical trial of the cancer-specific peptide vaccine S-588410

Announcement of the first-patient enrollment in Japan in phase I clinical trial of the out-licensed antibody from Immunas Pharma, Inc.